



Substitute for form 1449B

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Dated Filed: July 16, 2008

(use as many sheets as necessary)

Sheet 1 of 17

**Complete if Known**

Application Number 10/534,579  
Filing Date 11/14/2006  
First Named Inventor Xin Jiang  
Group Art Unit 1656  
Examiner Name Maryam Monshipouri  
Attorney Docket Number 059314-0401

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	6,372,724		Pelleg, <i>et al.</i>	April 16, 2002	
	A2	6,057,101		Nandabalan, <i>et al.</i>	May 2, 2000	
	A3	6,022,691		Bruice, <i>et al.</i>	February 8, 2000	
	A4	5,997,848		Patton, <i>et al.</i>	December 7, 1999	
	A5	5,932,435		Atkins, <i>et al.</i>	August 3, 1999	
	A6	5,914,236		Monsma, Jr., <i>et al.</i>	June 22, 1999	
	A7	5,910,434		Rigg, <i>et al.</i>	June 8, 1999	
	A8	5,840,484		Seilhamer, <i>et al.</i>	November 24, 1998	
	A9	5,837,458		Minshull, <i>et al.</i>	November 17, 1998	
	A10	5,804,413		DeLuca	September 8, 1998	
	A11	5,767,337		Roses, <i>et al.</i>	June 16, 1998	
	A12	5,707,618		Armentano, <i>et al.</i>	January 13, 1998	
	A13	5,686,242		Bruice, <i>et al.</i>	November 11, 1997	
	A14	5,605,662		Heller, <i>et al.</i>	February 25, 1997	
	A15	5,474,796		Brennan	December 12, 1995	
	A16	5,175,383		Leder, <i>et al.</i>	December 29, 1992	

**U.S. PROVISIONAL PATENT APPLICATION DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			
	B1	60/426,105	2002-11-13	ELLIOTT, Vicki	
	B2	60/433,215	2002-12-12	ELLIOTT, Vicki	
	B3	60/453,127	2003-03-07	SWARNAKAR, Anita	
	B4	60/454,801	2003-03-13	KABLE, Amy	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/534,579	
				Filing Date	
				11/14/2006	
				First Named Inventor	
Dated Filed: July 16, 2008				Xin Jiang	
(use as many sheets as necessary)				Group Art Unit	
				1656	
				Examiner Name	
				Maryam Monshipouri	
Sheet 2 of 17				Attorney Docket Number	
				059314-0401	

**U.S. PROVISIONAL PATENT APPLICATION DOCUMENTS**

		U.S. Patent Application Document			
	B5	60/465,495	2003-04-24	LEE, Soo	
	B6	60/465,619	2003-04-24	EMERLING, Brooke	
	B7	60/491,800	2003-08-01	BECHA, Shanya	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	C1		WO 95/35505	The Board of Trustees of the Leland Stanford Junior University	December 28, 1995		
	C2		WO 95/25116	California Institute of Technology	September 21, 1995		
	C3		WO 99/01554	Zymogenetics, Inc.	January 14, 1999		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D1	Adam, M.A. and A.D. Miller, "Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions," (1988) <u>J. Virol.</u> 62:3802-3806	
	D2	Altschul, S.F. <i>et al.</i> , "Basic local alignment search tool," (1990) <u>J. Mol. Biol.</u> 215:403-410	
	D3	Anderson, N.L. and J. Seilhamer, "A Comparison of Selected mRNA and Protein Abundances in Human Liver," (1997) <u>Electrophoresis</u> 18:533-537	
	D4	Antinozzi, P.A. <i>et al.</i> , "Metabolic engineering with recombinant adenoviruses," (1999) <u>Annu. Rev. Nutr.</u> 19:511-544	
	D5	Armentano, D. <i>et al.</i> , "Effect of internal viral sequences on the utility of retroviral vectors," (1987) <u>J. Virol.</u> 61:1647-1650	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/534,579
		<b>Filing Date</b>	11/14/2006
		<b>First Named Inventor</b>	Xin Jiang
		<b>Group Art Unit</b>	1656
		<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008		<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)			
Sheet	3	of	17

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D6	Arndt, G.M. <i>et al.</i> , "A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells," (2000) <u>Nucleic Acids Res.</u> 28:E15	
	D7	Ashkenazi, A. and V.M. Divit, "Apoptosis control by death and decoy receptors," (1999) <u>Curr. Opin. Cell Biol.</u> 11:255-260	
	D8	Baltimore, D., "Intracellular Immunization," (1988) <u>Nature</u> 335:395-396	
	D9	Bauer, G. <i>et al.</i> , "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) Replication After Transduction of Granulocyte Colony-Stimulating Factor-Mobilized D34 <sup>+</sup> Cells From HIV-1-Infected Donors Using Retroviral Vectors Containing Anti-HIV-1 Genes," (1997) <u>Blood</u> 89:2259-2267	
	D10	Bender, M.A. <i>et al.</i> , "Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region," (1987) <u>J. Virol.</u> 61:1639-1646	
	D11	Bitter, G.A. <i>et al.</i> , "Expression and Secretion Vectors for Yeast," (1987) <u>Methods Enzymol.</u> 153:516-544	
	D12	Blaese, R.M. <i>et al.</i> , "T Lymphocyte-Directed Gene Therapy for ADA <sup>+</sup> SCID: Initial Trial Results After 4 Years," (1995) <u>Science</u> 270:475-480	
	D13	Blind, M. <i>et al.</i> , "Cytoplasmic RNA modulators of an inside-out signal-transduction cascade," (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96:3606-3610	
	D14	Boado, R.J. <i>et al.</i> , "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," (1998) <u>J. Pharm. Sci.</u> 87:1308-1315	
	D15	Bolton, A.E. and W.M. Hunter, "The Labelling of Proteins to High Specific Radioactivities by Conjugation to a <sup>125</sup> I-Containing Acylating Agent," (1973) <u>Biochem. J.</u> 133:529-539	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/534,579
		<b>Filing Date</b>	11/14/2006
		<b>First Named Inventor</b>	Xin Jiang
		<b>Group Art Unit</b>	1656
		<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008		<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)			
Sheet	4	of	17

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D16	Bonyhadi, M.L., "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication," (1997) <u>J. Virol.</u> 71:4707-4716	
	D17	Bordignon, C. <i>et al.</i> , "Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA <sup>-</sup> Immunodeficient Patients," (1995) <u>Science</u> 270:470-475	
	D18	Boulay, J.-L. and H. Récipon, "Expression Vectors and Delivery Systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:445-450	
	D19	Brody, E.N. and L. Gold, "Aptamers as Therapeutic and Diagnosis Agents," (2000) <u>J. Biotechnol.</u> 74:5-13	
	D20	Broglie, R. <i>et al.</i> , "Light-Regulated Expression of a Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells," (1984) <u>Science</u> 224:838-843	
	D21	Brummelkamp, T.R. <i>et al.</i> , "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," (2002) <u>Science</u> 296:550-55	
	D22	Buller, R.M. <i>et al.</i> , "Decreased Virulence of Recombinant Vaccinia Virus Expression Vectors Is Associated With a Thymidine Kinase-Negative Phenotype," (1985) <u>Nature</u> 317:813-815	
	D23	Burge, C. and S. Karlin, "Finding the Genes in Genomic DNA," (1997) <u>J. Mol. Biol.</u> 268:78-94	
	D24	Burge, C. and S. Karlin, "Prediction of Complete Gene Structures in Human Genomic DNA," (1998) <u>Curr. Opin. Struct. Biol.</u> 8:346-354	
	D25	Burton, D.R., "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:10134-10137	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	5	of	17		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D26	Capecchi, M.R., "Altering the Genome by Homologous Recombination," (1989) <u>Science</u> 244:1288-1292	
	D27	Caruthers, M.H. <i>et al.</i> , "New chemical methods for synthesizing polynucleotides," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:215-223	
	D28	Cavazzana-Calvo, M. <i>et al.</i> , "Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease," (2000) <u>Science</u> 288:669-672	
	D29	Chang, C.-C. <i>et al.</i> , "Evolution of a Cytokine Using DNA Family Shuffling," (1999) <u>Nat. Biotechnol.</u> 17:793-797	
	D30	Chen, L. <i>et al.</i> , "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization," (1990) <u>Oncogene</u> 5:1391-1395	
	D31	Chicz, R.M. and F.Z. Regnier, "High-Performance Liquid Chromatography: Effective Protein Purification by Various Chromatographic Modes," (1990) <u>Methods Enzymol.</u> 182:392-421	
	D32	Christians, F.C. <i>et al.</i> , "Directed Evolution of Thymidine Kinase for AZT Phosphorylation Using DNA Family Shuffling," (1999) <u>Nat. Biotechnol.</u> 17:259-264	
	D33	Clarke, M.L. <i>et al.</i> , "Comparative Analysis of Artificial Antisense RNA Regulation in Fission Yeast and Human Cells," (2000) <u>Biochem. Biophys. Res. Commun.</u> 268:8-13	
	D34	Colbere-Garapin, F. <i>et al.</i> , "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells," (1981) <u>J. Mol. Biol.</u> 150:1-14	
	D35	Cole, S.P. <i>et al.</i> , "Human monoclonal antibodies," (1984) <u>Mol. Cell Biol.</u> 62:109-120	
	D36	Coruzzi, G. <i>et al.</i> , "Tissue-Specific and Light-Regulated Expression of a Pea Nuclear Gene Encoding the Small Subunit of rebusose-1,5-Bisphosphate Carboxylase," (1984) <u>EMBO J.</u> 3:1671-1680	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/534,579
		<b>Filing Date</b>	11/14/2006
		<b>First Named Inventor</b>	Xin Jiang
		<b>Group Art Unit</b>	1656
		<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008		<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)			
Sheet	6	of	17

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D37	Cote, R.J. <i>et al.</i> , "Generation of human monoclonal antibodies reactive with cellular antigen," (1983) <u>Proc. Natl. Acad. Sci. USA</u> 80:2026-2030	
	D38	Cramer, A. <i>et al.</i> , "Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling," (1996) <u>Nat. Biotechnol.</u> 14:315-319	
	D39	Crystal, R.G. <i>et al.</i> , "A Phase 1 Study, in Cystic Fibrosis Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombinant Adenovirus Carrying the cDNA of the Normal Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Lung," (1995) <u>Hum. Gene Therapy</u> 6:643-666	
	D40	Crystal, R.G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," (1995) <u>Science</u> 270:404-410	
	D41	Csete, M.E. <i>et al.</i> , "Efficient Gene Transfer to Pancreatic Islets Mediated by Adenoviral Vectors," (1995) <u>Transplantation</u> 27:263-268	
	D42	Cunningham, B.C. and J.A. Wells, "Rational design of receptor-specific variants of human growth hormone," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:3407-3411	
	D43	Dryga, S.A. <i>et al.</i> , "Identification of Mutations in a Sindbis Virus Variant Able to Establish Persistent Infection in BHK Cells: The Importance of a Mutation in the nsP2 Gene," (1997) <u>Virology</u> 228:74-83	
	D44	Dull, T. <i>et al.</i> , "A Third-Generation Lentivirus Vector with a Conditional Packaging System," (1998) <u>J. Virol.</u> 72:8463-8471	
	D45	Duplaa, C. <i>et al.</i> , "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <u>Anal. Biochem.</u> 212:229-236	
	D46	Eddy, S.R., "Hidden Markov Models," (1996) <u>Curr. Opin. Struct. Biol.</u> 6:361-365	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	7	of	17		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D47	Elbashir, S.M. <i>et al.</i> , "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," (2001) <u>Nature</u> 411:494-498)	
	D48	Engelhard, E.K. <i>et al.</i> , "The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus," (1994) <u>Proc. Natl. Acad. Sci. USA</u> 91:3224-3227	
	D49	Fields, S. and O. Song, "A Novel Genetic System to Detect Protein-Protein Interactions," (1989) <u>Nature</u> 340:245-246	
	D50	Fire, A. <i>et al.</i> , "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," (1998) <u>Nature</u> 391:806-811	
	D51	Gatti, R.A. <i>et al.</i> , "Localization of an Ataxia-Telangiectasia Gene to Chromosome," (1988) <u>Nature</u> 336:577-580	
	D52	Goins, W.F. <i>et al.</i> , "Herpes Simplex Virus Type 1 Vector-Mediated Expression of Nerve Growth Factor Protects Dorsal Root Ganglion Neurons from Peroxide Toxicity," (1999) <u>J. Virol.</u> 73:519-532	
	D53	Goldman, C.K. <i>et al.</i> , "In Vitro and In Vivo Gene Delivery Mediated by a Synthetic Polycationic Amino Polymer," (1997) <u>Nat. Biotechnol.</u> 15:462-466	
	D54	Gossen, M. and H. Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89:5547-5551	
	D55	Gossen, M. <i>et al.</i> , "Transcriptional Activation by Tetracyclines in Mammalian Cells," (1995) <u>Science</u> 268:1766-1769	
	D56	Graham, F.L. and A.J. Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," (1973) <u>Virology</u> 52:456-467	
	D57	Gura, T., "A silence that speaks volumes," (2000) <u>Nature</u> 404:804-808	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/534,579	
				Filing Date	
				11/14/2006	
				First Named Inventor	
Dated Filed: July 16, 2008				Xin Jiang	
(use as many sheets as necessary)				Group Art Unit	
				1656	
				Examiner Name	
				Maryam Monshipouri	
Sheet 8 of 17				Attorney Docket Number	
				059314-0401	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D58	Haft, D.H. <i>et al.</i> , "TIGRFAMs: a protein family resource for the functional identification of proteins," (2001) <u>Nucleic Acids Res.</u> 29:41-43	
	D59	Harrington, M.G., "Elution of Protein From Gels," (1990) <u>Methods Enzymol.</u> 182:488-495	
	D60	Harrington, J.J. <i>et al.</i> , "Formation of <i>De Novo</i> Centromere and Construction of First-Generation Human Artificial Microchromosomes," (1997) <u>Nat. Genet.</u> 15:345-355	
	D61	Hartman, S.C. and R.C. Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <u>Proc. Natl. Acad. Sci. USA</u> 85:8047-8051	
	D62	Heller, R.A. <i>et al.</i> , "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," (1997) <u>Proc. Natl. Acad. Sci. USA</u> 94:2150-2155	
	D63	Higgins, D.G. <i>et al.</i> , "CLUSTAL V: Improved Software for Multiple Sequence Alignment," (1992) <u>CABIOS</u> 8:189-191	
	D64	Higgins, D.G. and P.M. Sharp, "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," (1989) <u>CABIOS</u> 5:151-153	
	D65	Horn, T. <i>et al.</i> , "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for Gastric Inhibitory Polypeptide (GIP)," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:225-232	
	D66	Howard, A.D. <i>et al.</i> , "Orphan G-Protein-Coupled Receptors and Natural Ligand Discovery," (2001) <u>Trends Pharmacol. Sci.</u> 22:132-140	
	D67	Huse, W.D. <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," (1989) <u>Science</u> 246:1275-1281	
	D68	Ivics, Z., "Molecular Reconstruction of <i>Sleeping Beauty</i> , a <i>Tc1</i> -like Transposon from Fish, and Its Transposition in Human Cells," (1997) <u>Cell</u> 91:501-510	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/534,579	
				Filing Date	
				11/14/2006	
				First Named Inventor	
Dated Filed: July 16, 2008				Xin Jiang	
(use as many sheets as necessary)				Group Art Unit	
				1656	
				Examiner Name	
				Maryam Monshipouri	
Sheet 9 of 17				Attorney Docket Number	
				059314-0401	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D69	JANNE, J. et al., Biotechnol. Annu. Rev., 4:55-74 (1998).	
	D70	Khazaie, K. et al., "EGF Receptor in Neoplasia and Metastasis," (1993) <u>Cancer and Metastasis Rev.</u> 12:255-274	
	D71	Kimmel, A.R., "Identification and Characterization of Specific Clones: Strategy for Confirming the Validity of Presumptive Clones," (1987) <u>Methods Enzymol.</u> 152:507-511	
	D72	Kohler, G. et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," (1975) <u>Nature</u> 256:495-497	
	D73	Kozbor, D. et al., "Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas," (1985) <u>J. Immunol. Methods</u> 81:31-42	
	D74	Kwok, P.-Y. and Z. Gu, "Single Nucleotide Polymorphism Libraries: Why and How Are We Building Them?" (1999) <u>Mol. Med. Today</u> 5:538-543	
	D75	Lagerstrom, M. et al., "Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA," (1991) <u>PCR Methods Applic.</u> 1:111-119	
	D76	Lander, E.S. and D. Botstein, "Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms," (1986) <u>Proc. Natl. Acad. Sci. USA</u> 83:7353-7357	
	D77	Lee, S.W. et al. (1992), "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment," <u>Proc. Natl. Acad. Sci. USA</u> 89:2504-2508	
	D78	Letunic, I. et al., "Recent improvements to the SMART domain-based sequence annotation resource," (2002) <u>Nucleic Acids Res.</u> 30:242-244	
	D79	Liu, X. et al., Herpes Simplex Virus Mediated Gene Transfer to Primate Ocular Tissues," (1999) <u>Exp. Eye Res.</u> 169:385-395	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	10	of	17		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	D80	Logan, J. and T. Shenk, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:3655-3659			
	D81	Lois, C. <i>et al.</i> , "Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors," (2002) <u>Science</u> 295:868-872			
	D82	Lowman, H.B. <i>et al.</i> , "Mutational Analysis and Protein Engineering of Receptor-Binding Determinants in Human Placental Lactogen," (1991) <u>J. Biol. Chem.</u> 266:10982-10988			
	D83	Lowy, I. <i>et al.</i> , "Isolation of Transforming DNA: Cloning the Hamster apt Gene," (1980) <u>Cell</u> 22:817-823			
	D84	Manda <i>et al.</i> , "Identification of Genes (SPON2 and C20orf2) Differentially Expressed Between Cancerous and Noncancerous Lung Cells by mRNA Differential Display," (1999) <u>Genomics</u> 51:5-14			
	D85	Mantovani, A. <i>et al.</i> , "Decoy Receptors: A Strategy to Regulate Inflammatory Cytokines and Chemokines," (2001) <u>Trends Immunol.</u> 22:328-336			
	D86	Marshall, A. and J. Hodgson, "DNA Chips: an Array of Possibilities," (1998) <u>Nat. Biotechnol.</u> 16:27-31			
	D87	Marth, J.D., "Recent advances in gene mutagenesis by site-directed recombination," (1996) <u>Clin. Invest.</u> 97:1999-2002			
	D88	Matthews, D.J. and J.A. Wells, "Engineering an Interfacial Zinc Site to Increase Hormone-Receptor Affinity," (1994) <u>Chem. Biol.</u> 1:25-30			
	D89	McGregor, D.P. <i>et al.</i> , "Spontaneous Assembly of Bivalent Single Chain Antibody Fragments in <i>ESCHERICHIA COLI</i> ," (1994) <u>Mol. Immunol.</u> 31:219-226			
	D90	Melby, P.C. <i>et al.</i> , "Quantitative Measurement of Human Cytokine Gene Expression by Polymerase Chain Reaction," (1993) <u>J. Immunol. Methods</u> 159:235-244			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
Dated Filed: July 16, 2008				<b>Examiner Name</b>	Maryam Monshipouri
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0401
Sheet	11	of	17		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D91	Mendoze, L.G. <i>et al.</i> , "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)," (1999) <u>Biotechniques</u> 27:778-788	
	D92	Miller, A.D., "Progress Toward Human Gene Therapy," (1990) <u>Blood</u> 76:271-278	
	D93	Morgan, R.A. and W.F. Anderson, "Human Gene Therapy," (1993) <u>Annu. Rev. Biochem.</u> 62:191-217	
	D94	Morris, M.C. <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," (1997) <u>Nucleic Acids Res.</u> 25:2730-2736	
	D95	Morrison, S.L. <i>et al.</i> , "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855	
	D96	Muyldermans, S., "Single domain camel antibodies: current status," (2001) <u>J. Biotechnol.</u> 74:277-302	
	D97	Neuberger, M.S. <i>et al.</i> , "Recombinant Antibodies Possessing Novel Effector Functions," (1984) <u>Nature</u> 312:604-608	
	D98	Neumann, E. <i>et al.</i> , "Gene Transfer Into Mouse Lyoma Cells by Electroporation in High Electric Fields," (1982) <u>EMBO J.</u> 1:841-845	
	D99	Nowotny, P. <i>et al.</i> , "SNP analysis to dissect human traits," (2001) <u>Curr. Opin. Neurobiol.</u> 11:637-641	
	D100	Nuwaysir, E.F. <i>et al.</i> , "Microarrays and Toxicology: The Advent of Toxicogenomics," (1999) <u>Mol. Carcinog.</u> 24:153-159	
	D101	Orlandi, R. <i>et al.</i> , "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <u>Proc. Natl. Acad. Sci. USA</u> 86:3833-3837	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/534,579	
				Filing Date	
				11/14/2006	
				First Named Inventor	
Dated Filed: July 16, 2008				Xin Jiang	
(use as many sheets as necessary)				Group Art Unit	
				1656	
				Examiner Name	
				Maryam Monshipouri	
Sheet 12 of 17				Attorney Docket Number	
				059314-0401	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D102	Paddison, P.J. <i>et al.</i> , "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," (2002) <u>Genes Dev.</u> 16:948-958	
	D103	Parker, J.D. <i>et al.</i> , "Targeted gene walking polymerase chain reaction," (1991) <u>Nucleic Acids Res.</u> 19:3055-3060	
	D104	Perou, C.M. <i>et al.</i> , "Molecular portraits of human breast tumours," (2000) <u>Nature</u> 406:747-752	
	D105	Petersen <i>et al.</i> , "Gene Therapy Expression Profiling of Advanced Lung Cancer," (2000) <u>Int J. Cancer</u> , 86:512-517	
	D106	Poeschla, E. <i>et al.</i> , "Development of HIV Vectors for Anti-HIV Gene Therapy," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:11395-11399	
	D107	Ranga, U. <i>et al.</i> , "Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene," (1997) <u>J. Virol.</u> 71:7020-7029	
	D108	Ranga, U. <i>et al.</i> , "Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:1201-1206	
	D109	Rao, V.B., "Direct Sequencing of Polymerase Chain Reaction-Amplified DNA," (1994) <u>Anal. Biochem.</u> 216:1-14	
	D110	Rhodes, C.A., "Transformation of Maize by electroporation of Embryos," (1995) <u>Methods Mol. Biol.</u> 55:121-131	
	D111	Riviere, I. <i>et al.</i> , "Effects of Retroviral Vector Design on Expression of Human Adenosine Deaminase in Murine Bone Marrow Transplant Recipients Engrafted with Genetically Modified Cells," (1995) <u>Proc. Natl. Acad. Sci. USA</u> 92:6733-6737	
	D112	Roberge, J.Y. <i>et al.</i> , "A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support," (1995) <u>Science</u> 269:202-204	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	13	of	17		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	D113	Rossi, F.M.V. and H.M. Blau, "Recent Advances in Inducible Gene Expression Systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:451-456		
	D114	Rossi, J.J., "Therapeutic antisense and ribozymes," (1995) <u>Br. Med. Bull.</u> 51:217-225		
	D115	Sager, R. <i>et al.</i> , "Maspin: A Tumor Suppressing Serpin," (1996) <u>Curr. Top. Microbiol. Immunol.</u> 213:51-64		
	D116	Sandig, V. <i>et al.</i> , "Gene Transfer into Hepatocytes and Human Liver Tissue by Baculovirus Vectors," (1996) <u>Hum. Gene Ther.</u> 7:1937-1945		
	D117	Sarkar, G., "Restriction-Site PCR: A Direct Method of Unknown Sequence Retrieval Adjacent to a Known Locus by Using Universal Primers," (1993) <u>PCR Methods Applic.</u> 2:318-322		
	D118	Scanlon, K.J. <i>et al.</i> , "Oligonucleotide-Mediated Modulation of Mammalian Gene Expression," (1995) <u>FASEB J.</u> 9:1288-1296		
	D119	Scharf, D. <i>et al.</i> , "Heat Stress Promoters and Transcription Factors," (1994) <u>Results Probl. Cell Differ.</u> 20:125-162		
	D120	Schena, M. <i>et al.</i> , "Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:10614-10619		
	D121	Schena, M. <i>et al.</i> , "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray," (1995) <u>Science</u> 270:467-470		
	D122	Schultz, J. <i>et al.</i> , "SMART, a simple modular architecture research tool: Identification of signaling domains," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:5857-5864		
	D123	Schwarze, S.R. <i>et al.</i> , "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," (1999) <u>Science</u> 285:1569-1572		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	14	of	17		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	D124	Scorer, C.A. <i>et al.</i> , "Rapid Selection Using G418 of High Copy Number Transformants of <i>Pichia Pastoris</i> for High-Level Foreign Gene Expression," (1994) <u>Bio/Technology</u> 12:181-184			
	D125	Shalon, D. <i>et al.</i> , "A DNA Microarray System for Analyzing Complex DNA Samples Using Two-Color Fluorescent Probe Hybridization," (1996) <u>Genome Res.</u> 6:639-645			
	D126	Skerra, A., "'Anticalins': A New Class of Engineered Ligand-Binding Proteins With Antibody-Like Properties," (2001) <u>J. Biotechnol.</u> 74:257-275			
	D127	Slater, J.E. <i>et al.</i> , "Environmental and Occupational Disorders," (1998) <u>J. Allergy Clin. Immunol.</u> 102:469-475			
	D128	Steiner, S. and N.L. Anderson, "Expression Profiling in Toxicology—Potentials and Limitations," (2000) <u>Toxicol. Lett.</u> 112-113:467-471			
	D129	Su, L., "Hematopoietic Stem Cell-Based Gene Therapy for Acquired Immunodeficiency Syndrome: Efficient Transduction and Expression of RevM10 in Myeloid Cells In Vivo and In Vitro," (1997) <u>Blood</u> 89:2283-2290			
	D130	Takamatsu, N., "Expression of Bacterial Chloramphenicol Acetyltransferase Gene in Tobacco Plants Mediated by TRV-RNA," (1987) <u>EMBO J.</u> 6:307-311			
	D131	Takeda, S. <i>et al.</i> , "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences," (1985) <u>Nature</u> 314:452-454			
	D132	Taylor, J.G. <i>et al.</i> , "Deconstructing Type 2 Diabetes," (2001) <u>Trends Mol. Med.</u> 7:507-512			
	D133	Taylor, P.C. <i>et al.</i> , "Immunotherapy for Rheumatoid Arthritis," (2001) <u>Curr. Opin. Immunol.</u> 13:611-616			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	15	of	17		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D134	Thomson, J.A. <i>et al.</i> , Embryonic Stem Cell Lines Derived from Human Blastocysts," (1998) <u>Science</u> 282:1145-1147	
	D135	Trask, B.J., "Fluorescence <i>in situ</i> Hybridization," (1991) <u>Trends Genet.</u> 7:149-154	
	D136	Triglia, T. <i>et al.</i> , "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," (1988) <u>Nucleic Acids Res.</u> 16:8186	
	D137	Uckert, W. and W. Walther, "Retrovirus-Mediated Gene Transfer in Cancer Therapy," (1994) <u>Pharmacol. Ther.</u> 63:323-347	
	D138	Ulrix, W. <i>et al.</i> , "The Differentiation-Related Gene 1, <i>Drg1</i> , Is Markedly Upregulated by Androgens in LNCaP Prostatic Adenocarcinoma Cells," (1999) <u>FEBS Lett</u> 455:23-26	
	D139	Van Heeke, G. and S.M. Schuster, "Expression of Human Synthetase in <i>Escherichia coli</i> ," (1989) <u>J. Biol. Chem.</u> 264:5503-5509	
	D140	Verma, I.M. and N. Somia, "Gene therapy - promises, problems and prospects," (1997) <u>Nature</u> , 18:389:239-242	
	D141	Wagner, K.U. <i>et al.</i> , "Cre-mediated gene deletion in the mammary gland," (1997) <u>Nucleic Acids Res.</u> , 25:4323-4330	
	D142	Wahl, G.M. and S.L. Berger, "Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations," (1987) <u>Methods Enzymol.</u> 152:399-407	
	D143	Wang <i>et al.</i> , "Identification of Genes Differentially Over-Expressed in Lung Squamous Cell Carcinoma Using Combination of cDNA subtraction and microarray Analysis," (2000) <u>Oncogene</u> 19:1519-1528	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/534,579
				<b>Filing Date</b>	11/14/2006
				<b>First Named Inventor</b>	Xin Jiang
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Maryam Monshipouri
Dated Filed: July 16, 2008				<b>Attorney Docket Number</b>	059314-0401
(use as many sheets as necessary)					
Sheet	16	of	17		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	D144	Way, J.M. <i>et al.</i> , "Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor $\gamma$ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-sensitive Tissues," (2001) <u>Endocrinology</u> 142:1269-1277		
	D145	Weiss, G.A. and H.B. Lowman, "Anticalins Versus Antibodies: Made-To-Order Binding Proteins for Small Molecules," (2000) <u>Chem. Biol.</u> 7:R177-R184		
	D146	Wigler, M. <i>et al.</i> , "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells," (1977) <u>Cell</u> 11:223-232		
	D147	Wigler, M. <i>et al.</i> , "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <u>Proc. Natl. Acad. Sci. USA</u> 77:3567-3570		
	D148	Winter, G. <i>et al.</i> , "Man-Made Antibodies," (1991) <u>Nature</u> 349:293-299		
	D149	Wise, A. <i>et al.</i> , "Target Validation of G-Protein Coupled Receptors," (2002) <u>Drug Discovery Today</u> 7:235-246		
	D150	Wistuba, I.I. <i>et al.</i> , "Comparison of Features of Human Breast Cancer Cell Lines and Their Corresponding Tumors," (1998) <u>Clin. Cancer Res.</u> 4:2931-2938		
	D151	Xu, H. <i>et al.</i> , "Viral Transduction of <i>trkA</i> Into Cultured Nodose and Spinal Motor Newrons Conveys NGF Responsiveness," (1994) <u>Dev. Biol.</u> 163:152-161		
	D152	Yu, M. <i>et al.</i> , "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," (1993) <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344		
	D153	Zabner, J. <i>et al.</i> , "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Masal Epithelia of Patients with Cystic Fibrosis," (1993) <u>Cell</u> 75:207-216		
	D154	Zhou, Z. <i>et al.</i> , "Up-Regulation of Human Secreted Frizzled Homolog in Apoptosis and its Down-Regulation in Breat Tumors," (1998) <u>Int. J. Cancer</u> 78:95-99		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Dated Filed: July 16, 2008  <i>(use as many sheets as necessary)</i>				Application Number	10/534,579
				Filing Date	11/14/2006
				First Named Inventor	Xin Jiang
				Group Art Unit	1656
				Examiner Name	Maryam Monshipouri
Sheet	17	of	17	Attorney Docket Number	059314-0401

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	D155	Zufferey, R. <i>et al.</i> , "Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery," (1998) <u>J. Virol.</u> 72:9873-9880		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.